Tag: axess
Xeltis completes enrolment in EU pivotal trial
Xeltis has announced the completion of enrolment in its EU pivotal trial for aXess, its restorative vascular access conduit, in adults with end-stage renal...
Xeltis receives IDE approval from US FDA for haemodialysis vascular access...
Xeltis has announced that it has gained approval from the US Food and Drug Administration (FDA) for an investigational device exemption (IDE) submission to...
Xeltis presents six-month first-in-human data on aXess graft
Xeltis has presented “highly-encouraging” six-month data from its first-in-human (FIH) aXess vascular graft trial at the 13th Congress of the Vascular Access Society (VAS;...
Xeltis starts pivotal clinical trial of “first-ever” restorative synthetic haemodialysis access...
Xeltis announced today the initiation of a pivotal trial with the “first-ever” restorative synthetic haemodialysis access graft, dubbed ‘Axess’.
The first two patients have been...
Xeltis presents “promising” first-in-human data on restorative haemodialysis access graft
Xeltis today announced what it describes as “very promising” preliminary efficacy and safety results from one of the centres participating in the AXESS study—a...
Restorative Axess graft demonstrates promising patency and safety in first-in-human study
The preliminary results from a clinical trial assessing a restorative haemodialysis access graft have shown promising early puncturing, patency and safety data. These findings...
